title: [Relationship between hormone therapy in women with ovarian malignancy and prognosis].
abstract: OBJECTIVE
  To explore the relationship between hormone therapy (HT) in women with ovarian malignancy and prognosis.
  
  
  METHODS
  HT was used in 31 patients with ovarian cancer after surgery, and 44 cases with ovarian cancer served as control. The expression of estrogen receptor (ER)alpha, ERbeta and progesterone receptor (PR) was detected by immunohistochemical staining respectively. The level of serum calcitonin and transforming growth factor alpha (TGFalpha) was detected by radio-immune and enzyme-linked immunosorbent assay pre- or post-surgery, as well as half a year to one year later post-surgery respectively in these cases. The survival curve of Kaplan-Meier and log-rank test as well as scale risk of Cox model were used to analyze the relationship between HT and prognosis of ovarian cancer.
  
  
  RESULTS
  (1) The results of log-rank test showed that there was no difference in survival curve of patients with or without HT [(1108 +/- 52), (1086 +/- 43) d; P = 0.940]; the results of scale risk of Cox model also showed that HT was not an independent prognosis factor for patients with HT. (2) There was no relationship with HT and the accumulated survival in patients with either positive or negative expression of ERalpha, ERbeta and PR in tissue; as well as between HT and the level of serum TGFalpha pre-, post-surgery, or half a year to one year after surgery. (3) The level of serum calcitonin in patients without HT post-surgery half a year to one year later was higher than that pre-surgery [(141 +/- 13), (95 +/- 11) microg/L; P < 0.05], but there was no significant difference between patients with HT half a year to one year later post-surgery and pre-surgery [(90 +/- 18) microg/L, (93 +/- 14) microg/L; P > 0.05]. (4) There was a significant difference in body and emotion function between HT and without HT groups [(1.84 +/- 1.50), (1.45 +/- 0.82); (12.69 +/- 10.20), (12.90 +/- 11.61); P < 0.05], as well as in sex quality and autonomic nerve maladjustment and in the special list made [(1.05 +/- 0.74), (1.77 +/- 1.08); (10.10 +/- 3.21), (13.09 +/- 4.30); P < 0.05].
  
  
  CONCLUSIONS
  There is no adverse influence on prognosis in using of HT for patients with ovarian cancer after surgery. HT for patients with ovarian cancer post-surgery can help keep a stable level of serum calcitonin as well as improve the quality of life.
authors.affiliation: Department of Gynecologic Oncology, Tumor Hospital, Guangxi Medical University, Nanning 530021, China. lili@gxmu.net.cn
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Zhong-Mian
authors.initials: ZM
authors.lastname: Pan
authors.forename: Xin-Qiu
authors.initials: XQ
authors.lastname: Chen
authors.forename: Kun
authors.initials: K
authors.lastname: Gao
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Luo
authors.forename: Zhong-Qiang
authors.initials: ZQ
authors.lastname: Yao
authors.forename: Xin-Qiang
authors.initials: XQ
authors.lastname: Liang
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: De-Sheng
authors.initials: DS
authors.lastname: Yao
mesh_terms: D000328:Adult; D002116:Calcitonin / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D017698:Postmenopause; D011379:Prognosis; D011788:Quality of Life; D011800:Quinestrol / Q000008:administration & dosage / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D016211:Transforming Growth Factor alpha / Q000097:blood; D055815:Young Adult
chemical_list: D004967:Estrogens; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016211:Transforming Growth Factor alpha; D002116:Calcitonin; D008525:Medroxyprogesterone; D011800:Quinestrol